drugset / Trial / NCT00129506

Comparing Methotrexate Followed by Misoprostol to Misoprostol Alone for Early Abortion

NCT00129506

RandomizedParallel-groupOpen-labelTreatment

Summary

Background: In most countries in which abortion is legal, medical abortions are induced with mifepristone and misoprostol. Since mifepristone is expensive and unavailable in many countries, it is important to find other regimens. Methotrexate, which is used with misoprostol in Canada, is also difficult to obtain in many countries. Misoprostol is inexpensive and available in almost all countries. A report from Nigeria found that 98% of 100 women aborted within 24 hours of using misoprostol given both sublingually and vaginally. Method: This will be a randomized controlled trial of the usual regimen used in Canada, methotrexate 50 mg/m2 intramuscularly (IM) followed three days later by 800 mcg vaginal misoprostol to the Nigerian regimen of 400 mcg sublingual misoprostol with 400 mcg vaginal misoprostol. The main outcome measure will be a completed abortion within the first week with secondary outcome measures including total surgery rate, time to abortion, complications, pain, side effects and patient satisfaction. Rationale: If the investigators can find an inexpensive, easily available, method of medical abortion, it will save many lives in third world countries.

Timeline

Start
2005-05
Primary completion
2005-09
Completion
2005-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Methotrexate Small molecule 50 mg/m2 Intramuscular
Subject Misoprostol Other / unclassified 400 ug Other
Subject Misoprostol Other / unclassified 800 ug Other

Indications

No indication recorded.